Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT02460276 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.

NCT NCT02460276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02460276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Lead sponsor
Lund University Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2015
Completion date
December 31, 2019
Enrollment
50 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory mantle cell lymphoma